2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Tuesday, October 23, 2018

9:00AM-11:00AM: Abstract Number: 2485

Comparison of Risk for Infection-Related Hospitalization and Associated Costs of Biologic Experienced Rheumatoid Arthritis Patients Treated with Abatacept Versus Other Targeted Disease Modifying Antirheumatic Drugs

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

9:00AM-11:00AM: Abstract Number: 2408

Comparison of the Tear Cytokine and Chemokine Profile of Children with JIA and JIA-Associated Uveitis

Pediatric Rheumatology – Clinical Poster III: Juvenile Idiopathic Arthritis and Uveitis

9:00AM-11:00AM: Abstract Number: 2718

Comparison of Various ANCA Detection Methods in Predominantly MPO ANCA-Associated Vasculitis Cohort

Vasculitis – ANCA-Associated Poster II

9:00AM-11:00AM: Abstract Number: 2630

Complement C4d Split Products in Combination with Lupus Anticoagulant and Low Complement Associate with Thrombosis in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2300

Compliance with Screening and Supplementation Guidelines for Glucocorticoid-Induced Osteoporosis, How Bad Did We Do This Time?

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 1980

Comprehensive Association Analysis between Rare and Common ABCG2 Variants and Gout Susceptibility

Genetics, Genomics and Proteomics Poster

9:00AM-11:00AM: Abstract Number: 2222

Construct Validity of Provisional Remission Criteria for Gout: A Dual Energy CT Study

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 2236

Contemporary Comorbidity Burden of Gout and Hyperuricemia in the US during the Past Decade (National Health And Nutrition Examination Survey [NHANES] 2007-2016)

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 2653

Contraceptive Documentation in Systemic Lupus Erythematosus Patients at a Safety Net Hospital

Systemic Lupus Erythematosus – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2709

Conversion of Normal Mean Pulmonary Arterial Pressure to Pulmonary Hypertension in Systemic Sclerosis – a Longitudinal Observational Study

Systemic Sclerosis and Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 2525

Correlation Analysis between Sirukumab Exposure and Selected Safety Events Following Subcutaneous Administration Using Pooled Phase 3 Data in Rheumatoid Arthritis

Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds

9:00AM-11:00AM: Abstract Number: 2428

Correlation between Antibodies to the Phosphotidylserine/Prothrombin Complex (aPS/PT) and Anti-β2glycoprotein-1-Domain 1 (anti-β2GP1-D1) and Vascular Thrombosis (VT) and/or Pregnancy Morbidity (PM)

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 2448

Correlation between Long-Term Low-Dose Steroid Administration and Reactivation of Hepatitis B Virus in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

9:00AM-11:00AM: Abstract Number: 2624

Cost-Effectiveness of Swapping Strategy for Established Psoriatic Arthritis and Immediate Versus Standard Swapping Strategy for Early Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2278

Cryopyrinopathy across Generations: Longterm Disease Outcome

Miscellaneous Rheumatic and Inflammatory Diseases Poster III: Sarcoid, Inflammatory Eye Disease, and Autoinflammatory Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].